Stress Urinary Incontinence Drug Pipeline Analysis Report 2025
Description
Stress urinary incontinence is a condition characterized by involuntary leakage of urine during physical activity or stress. The disorder affects around 10-20% of the population, predominantly affecting women. There is a high unmet clinical need for better therapies, as current treatment options, such as pelvic floor exercises, medications, and surgical interventions, often fail to deliver lasting results. Furthermore, the growing focus on innovative drug development and minimally invasive treatments is likely to support pipeline growth in the coming years, providing hope for more effective and long-term management solutions for stress urinary incontinence.
Report Coverage
The Stress Urinary Incontinence Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into stress urinary incontinence therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for stress urinary incontinence. The stress urinary incontinence report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The stress urinary incontinence pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with stress urinary incontinence treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to stress urinary incontinence.
Stress Urinary Incontinence Drug Pipeline Outlook
Stress urinary incontinence is the involuntary leakage of urine due to physical stress, such as coughing, sneezing, or exercising. It occurs when the pelvic floor muscles and bladder sphincter weaken, impairing their ability to retain urine during physical activity. This condition primarily affects women, especially after childbirth or menopause.
Stress urinary incontinence treatments include behavioral therapies, medications, and surgical options. Conservative treatments like pelvic floor exercises strengthen muscles, while medications manage symptoms. In severe cases, surgical interventions such as slings or bladder neck suspension may provide long-term relief. Emerging drug therapies are being developed to address underlying causes.
Stress Urinary Incontinence Epidemiology
A 2023 report indicates that stress urinary incontinence (SUI) is globally prevalent, with prevalence rates increasing across various regions. In the United States, up to 60% of women in certain communities are affected. The condition significantly impacts quality of life, leading to physical, social, psychological, and financial challenges. In the Middle East, prevalence rates range from 20.3% to 54.8%.
Stress Urinary Incontinence Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of stress urinary incontinence drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II holds a significant share of the total stress urinary incontinence clinical trials.
Stress Urinary Incontinence – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the stress urinary incontinence pipeline analysis include small molecules, monoclonal antibodies, and peptides. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for stress urinary incontinence.
Stress Urinary Incontinence Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR stress urinary incontinence drug report insights include the profiles of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in stress urinary incontinence clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for stress urinary incontinence. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of stress urinary incontinence drug candidates.
Biological: AMDC-USR (iltamiocel)
The "CELLEBRATE" Phase 3 clinical trial, sponsored by Cook MyoSite, evaluates the efficacy and safety of Autologous Muscle Derived Cells (AMDC-USR) for urinary sphincter repair compared to a placebo in adult women with post-surgical stress urinary incontinence. The study aims to assess the reduction in incontinence episodes. The study is expected to be completed by February 2026 and involves around 96 participants.
Drug: VMB-100
The Phase 2a study, sponsored by Versameb AG, aims to evaluate the safety, tolerability, and efficacy of VMB-100 in females with moderate stress urinary incontinence. VMB-100, an mRNA encoding IGF-1, is injected into the urethral sphincter to promote muscle regeneration. The study, expected to conclude by November 2028, will involve 30 participants and focus on improving sphincter function to alleviate incontinence.
Reasons To Buy This Report
The Stress Urinary Incontinence Drug Pipeline Insight Report offers a strategic overview of the latest and future landscape of treatments for stress urinary incontinence. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within stress urinary incontinence pipeline insights.
Key Questions Answered in the Stress Urinary Incontinence – Pipeline Insight Report
Urinary Incontinence Drug Pipeline Analysis Report
Global Clinical Trials Market
Report Coverage
The Stress Urinary Incontinence Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into stress urinary incontinence therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for stress urinary incontinence. The stress urinary incontinence report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The stress urinary incontinence pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with stress urinary incontinence treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to stress urinary incontinence.
Stress Urinary Incontinence Drug Pipeline Outlook
Stress urinary incontinence is the involuntary leakage of urine due to physical stress, such as coughing, sneezing, or exercising. It occurs when the pelvic floor muscles and bladder sphincter weaken, impairing their ability to retain urine during physical activity. This condition primarily affects women, especially after childbirth or menopause.
Stress urinary incontinence treatments include behavioral therapies, medications, and surgical options. Conservative treatments like pelvic floor exercises strengthen muscles, while medications manage symptoms. In severe cases, surgical interventions such as slings or bladder neck suspension may provide long-term relief. Emerging drug therapies are being developed to address underlying causes.
Stress Urinary Incontinence Epidemiology
A 2023 report indicates that stress urinary incontinence (SUI) is globally prevalent, with prevalence rates increasing across various regions. In the United States, up to 60% of women in certain communities are affected. The condition significantly impacts quality of life, leading to physical, social, psychological, and financial challenges. In the Middle East, prevalence rates range from 20.3% to 54.8%.
Stress Urinary Incontinence Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of stress urinary incontinence drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibodies
- Peptide
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II holds a significant share of the total stress urinary incontinence clinical trials.
Stress Urinary Incontinence – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the stress urinary incontinence pipeline analysis include small molecules, monoclonal antibodies, and peptides. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for stress urinary incontinence.
Stress Urinary Incontinence Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR stress urinary incontinence drug report insights include the profiles of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in stress urinary incontinence clinical trials:
- Levee Medical, Inc.
- Versameb AG
- Cook MyoSite
- TBF Genie Tissulaire
- GCP-Service International Ltd. & Co. KG
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for stress urinary incontinence. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of stress urinary incontinence drug candidates.
Biological: AMDC-USR (iltamiocel)
The "CELLEBRATE" Phase 3 clinical trial, sponsored by Cook MyoSite, evaluates the efficacy and safety of Autologous Muscle Derived Cells (AMDC-USR) for urinary sphincter repair compared to a placebo in adult women with post-surgical stress urinary incontinence. The study aims to assess the reduction in incontinence episodes. The study is expected to be completed by February 2026 and involves around 96 participants.
Drug: VMB-100
The Phase 2a study, sponsored by Versameb AG, aims to evaluate the safety, tolerability, and efficacy of VMB-100 in females with moderate stress urinary incontinence. VMB-100, an mRNA encoding IGF-1, is injected into the urethral sphincter to promote muscle regeneration. The study, expected to conclude by November 2028, will involve 30 participants and focus on improving sphincter function to alleviate incontinence.
Reasons To Buy This Report
The Stress Urinary Incontinence Drug Pipeline Insight Report offers a strategic overview of the latest and future landscape of treatments for stress urinary incontinence. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within stress urinary incontinence pipeline insights.
Key Questions Answered in the Stress Urinary Incontinence – Pipeline Insight Report
- What is the current landscape of stress urinary incontinence pipeline drugs?
- Which companies/institutions are developing stress urinary incontinence emerging drugs?
- How many phase II drugs are currently present in stress urinary incontinence pipeline drugs?
- Which company is leading the stress urinary incontinence pipeline development activities?
- What is the current stress urinary incontinence therapeutic assessment?
- What are the opportunities and challenges present in the stress urinary incontinence drug pipeline landscape?
- What is the efficacy and safety profile of stress urinary incontinence pipeline drugs?
- Which companies/institutions are involved in stress urinary incontinence collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in stress urinary incontinence?
Urinary Incontinence Drug Pipeline Analysis Report
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Stress Urinary Incontinence
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Stress Urinary Incontinence
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Stress Urinary Incontinence: Epidemiology Snapshot
- 5.1 Stress Urinary Incontinence Incidence by Key Markets
- 5.2 Stress Urinary Incontinence – Patients Seeking Treatment in Key Markets
- 6 Stress Urinary Incontinence: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Stress Urinary Incontinence: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Stress Urinary Incontinence, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Stress Urinary Incontinence Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Stress Urinary Incontinence Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Biological: AMDC-USR (iltamiocel)
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 Stress Urinary Incontinence Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: VMB-100
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Biological: Autologous Muscle Precursor Cells
- 11.2.3 Other Drugs
- 12 Stress Urinary Incontinence Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug 1
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Stress Urinary Incontinence Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Stress Urinary Incontinence, Key Drug Pipeline Companies
- 14.1 Levee Medical, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Versameb AG
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Cook MyoSite
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 TBF Genie Tissulaire
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 GCP-Service International Ltd. & Co. KG
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
